MBS495082 is a ready-to-use microwell, strip-or-full plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Kynurenine, ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing Kynurenine. The ELISA analytical biochemical technique of the MBS495082 kit is based on Kynurenine antibody-Kynurenine antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect Kynurenine antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, Kynurenine. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

Intended Uses:

Enzyme Immunoassay for the quantitative determination of L-Kynurenine in serum, plasma and various biological samples. After acylation Kynurenine is quantitatively determined by ELISA. The competitive ELISA uses the microtiter plate format. The antigen is bound to the solid phase of the microtiter plate. The acylated standards, controls and samples and the solid phase bound analyte compete for a fixed number of antibody binding sites. When the system is in equilibrium, free antigen and free antigen-antibody complexes are removed by washing. The antibody bound to the solid phase is detected by an anti-rabbit IgG-peroxidase conjugate using TMB as a substrate. The reaction Is monitored at 450 nm. Quantification of unknown samples is achieved by comparing their absorbance with a reference curve prepared with known standards.

Principle of the Assay:

Enzyme Immunoassay for the quantitative determination of L-Kynurenine in serum, plasma and various biological samples. After acylation Kynurenine is quantitatively determined by ELISA. The competitive ELISA uses the microtiter plate format. The antigen is bound to the solid phase of the microtiter plate. The acylated standards, controls and samples and the solid phase bound analyte compete for a fixed number of antibody binding sites. When the system is in equilibrium, free antigen and free antigen-antibody complexes are removed by washing. The antibody bound to the solid phase is detected by an anti-rabbit IgG-peroxidase conjugate using TMB as a substrate. The reaction Is monitored at 450 nm. Quantification of unknown samples is achieved by comparing their absorbance with a reference curve prepared with known standards.

艾美捷 MyBioSource犬尿氨酸 ELISA試劑盒是一種即用型微孔板或全板 ELISA（酶聯(lián)免疫吸附測(cè)定）試劑盒，用于分析生物樣品中犬尿氨酸、ELISA 試劑盒目標(biāo)分析物的存在。試劑盒標(biāo)準(zhǔn)品或陽(yáng)性對(duì)照的濃度梯度為含有犬尿氨酸的生物研究樣品提供了理論上的試劑盒檢測(cè)范圍。

艾美捷 MyBioSource犬尿氨酸 ELISA試劑盒測(cè)定原理：

酶免疫測(cè)定法用于定量測(cè)定血清、血漿和各種生物樣品中的 L-犬尿氨酸。?；笕虬彼嵬ㄟ^(guò)ELISA定量測(cè)定。競(jìng)爭(zhēng)性 ELISA 使用微量滴定板格式。抗原與微量滴定板的固相結(jié)合。酰化的標(biāo)準(zhǔn)品、對(duì)照品和樣品與固相結(jié)合的分析物競(jìng)爭(zhēng)固定數(shù)量的抗體結(jié)合位點(diǎn)。當(dāng)系統(tǒng)處于平衡狀態(tài)時(shí)，通過(guò)洗滌除去游離抗原和游離抗原-抗體復(fù)合物。通過(guò)使用 TMB 作為底物的抗兔 IgG-過(guò)氧化物酶偶聯(lián)物檢測(cè)與固相結(jié)合的抗體。在 450 nm 監(jiān)測(cè)反應(yīng)。未知樣品的定量是通過(guò)將它們的吸光度與用已知標(biāo)準(zhǔn)制備的參考曲線(xiàn)進(jìn)行比較來(lái)實(shí)現(xiàn)的。

艾美捷 MyBioSource犬尿氨酸 ELISA試劑盒典型檢測(cè)數(shù)據(jù)/標(biāo)準(zhǔn)曲線(xiàn)（僅供參考）：

相關(guān)參考文獻(xiàn)：

(1) Barone, P. (2019). The 'Yin' and the 'Yang' of the kynurenine pathway: excitotoxicity and neuroprotection

imbalance in stress-induced disorders. Behav Pharmacol, 30(2 and 3-Spec Issue), 163-186.

doi:10.1097/fbp.0000000000000477

(2) Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., . . . Maes, M. (2002).

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy

are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol,

22(1), 86-90. doi:10.1097/00004714-200202000-00014

(3) Bryleva, E. Y., & Brundin, L. (2017). Kynurenine pathway metabolites and suicidality.

Neuropharmacology, 112(Pt B), 324-330. doi:10.1016/j.neuropharm.2016.01.034